Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History JNJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics JNJ

Aristocrat - 25 or more consecutive years of dividend increases

Max Ratio

5.34

5Y Dividend Growth

31.00 %

Consecutive Years

40 years

5Y Average Payout Ratio

62.05 %
Forward Annual Dividend Yield 3.19 %
Consecutive Years 40
Forward Annual Dividend 5.20 USD
Consistent Years 40
Dividend CAGR 3Y 5.43 %
Continuous Dividends
Dividend CAGR 5Y 5.54 %
Payout Ratio TTM 44.48 %
Dividend CAGR 10Y 5.93 %
Ex Dividend Date 26.08.2025

Johnson & Johnson

JNJ
Current price
162.98 USD -0.2 USD (-0.12%)
Last closed 164.78 USD
ISIN US4781601046
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 396 472 221 696 USD
Yield for 12 month +4.86 %
1Y
3Y
5Y
10Y
15Y
JNJ
21.11.2021 - 28.11.2021

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey. Address: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

169.18 USD

P/E Ratio

18.35

Dividend Yield

3.19 %

Financials JNJ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures JNJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+88 821 000 000 USD

Last Year

+85 159 000 000 USD

Current Quarter

Last Quarter

+21 893 000 000 USD

Current Year

+61 350 000 000 USD

Last Year

+58 413 000 000 USD

Current Quarter

+16 115 000 000 USD

Last Quarter

+14 536 000 000 USD
EBITDA 30 025 000 960 USD
Operating Margin TTM 29.41 %
Price to Earnings 18.35
Return On Assets TTM 7.77 %
PEG Ratio 1.07
Return On Equity TTM 29.45 %
Wall Street Target Price 169.18 USD
Revenue TTM 89 330 999 296 USD
Book Value 32.47 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2.40 %
Dividend Yield 3.19 %
Gross Profit TTM 61 549 998 080 USD
Earnings per share 8.98 USD
Diluted Eps TTM 8.98 USD
Most Recent Quarter II 2025
Quarterly Earnings Growth YOY 238.80 %
Profit Margin 24.42 %

Stock Valuation JNJ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 18.35
Forward PE 14.81
Enterprise Value Revenue 4.37
Price Sales TTM 4.44
Enterprise Value EBITDA 11.26
Price Book MRQ 4.83

Technical Indicators JNJ

For 52 Weeks

138.38 USD 168.55 USD
50 Day MA 153.92 USD
Shares Short Prior Month 22 801 009
200 Day MA 155.25 USD
Short Ratio 2.08
Shares Short 16 330 615
Short Percent 0.68 %